Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen

dc.contributor.authorSingh, Sanjay
dc.contributor.authorGumbo, Tawanda
dc.contributor.authorAlffenaar, Jan-Willem
dc.contributor.authorBoorgula, Gunavanthi D.
dc.contributor.authorShankar, Prem
dc.contributor.authorThomas, Tania A.
dc.contributor.authorDheda, Keertan
dc.contributor.authorMalinga, Lesibana Anthony
dc.contributor.authorRaj, Prithvi
dc.contributor.authorAryal, Santosh
dc.contributor.authorSrivastava, Shashikant
dc.date.accessioned2024-05-27T08:41:58Z
dc.date.issued2023-12
dc.descriptionDATA AVAILABILITY STATEMENT : Upon a reasonable request, the raw data for the results presented in the manuscript are available from the corresponding author.en_US
dc.description.abstractPlease read abstract in the article.en_US
dc.description.departmentMedical Microbiologyen_US
dc.description.embargo2024-10-23
dc.description.librarianhj2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the University of Texas System STARS award, the Department of Pulmonary Immunology, UT Health Science Center at Tyler, Texas, USA.en_US
dc.description.urihttp://www.elsevier.com/locate/ijantimicagen_US
dc.identifier.citationSingh, S., Gumbo, T., Alffenaar, J.-W. et al. 2023, 'Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen', International Journal of Antimicrobial Agents, vol. 62, no. 6, art. 106968, pp. 1-8, doi : 10.1016/j.ijantimicag.2023.106968.en_US
dc.identifier.issn0924-8579 (print)
dc.identifier.issn1872-7913 (online)
dc.identifier.other10.1016/j.ijantimicag.2023.106968
dc.identifier.urihttp://hdl.handle.net/2263/96243
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rights© 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in International Journal of Antimicrobial Agents. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in International Journal of Antimicrobial Agents, vol. 62, no. 6, art. 106968, pp. 1-8, doi : 10.1016/j.ijantimicag.2023.106968.en_US
dc.subjectBeta-lactamsen_US
dc.subjectPharmacokineticsen_US
dc.subjectPharmacodynamicsen_US
dc.subjectTuberculosis (TB)en_US
dc.subjectβ-lactamase inhibitors (BLIs)en_US
dc.subjectBedaquiline-pretonamid-linezolid (BPaL)en_US
dc.subjectHollow fiber model systemen_US
dc.subjectMultidrug-resistant tuberculosis (MDR-TB)en_US
dc.subjectMycobacterium tuberculosis (MTB)en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleMeropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimenen_US
dc.typePostprint Articleen_US

Files

Original bundle

Now showing 1 - 3 of 3
Thumbnail Image
Name:
Singh_MeropenemVaborbactam_2023.pdf
Size:
1 MB
Format:
Adobe Portable Document Format
Description:
Postprint Article
Download
Thumbnail Image
Name:
Singh_MeropenemVaborbactamSuppl1_2023.pdf
Size:
131.48 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Material 1
Download
Thumbnail Image
Name:
Singh_MeropenemVaborbactamSuppl2_2023.jpg
Size:
66.56 KB
Format:
Joint Photographic Experts Group/JPEG File Interchange Format (JFIF)
Description:
Supplementary Material 2
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (Medical Microbiology)
Research Articles (University of Pretoria)
Simple item page